S
TRDA icon

SignatureFD’s Entrada Therapeutics TRDA Stock Holding History

SignatureFD’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-208
Closed -$2.63K – 3640
2026
Q1 		$2.63K Buy
208
+41
+25% +$470 ﹤0.01% 2984
2025
Q4 		$1.72K Buy
+167
New +$1.41K ﹤0.01% 3009
2025
Q3 		– Sell
-53
Closed -$356 – 3483
2025
Q2 		$356 Buy
+53
New +$426 ﹤0.01% 3150

Other funds holding TRDA

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

SignatureFD's TRDA Position: Q2 2026 in Review

SignatureFD sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 208 shares — an estimated $2.63K sold.

SignatureFD first reported a position in TRDA in Q2 2025 and held it in 3 quarters. The position peaked at $2.63K in Q1 2026. 15 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • SignatureFD reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • SignatureFD sold 208 Entrada Therapeutics shares in Q2 2026, an estimated $2.63K.
  • SignatureFD first reported a position in Entrada Therapeutics in Q2 2025 and held it in 3 quarters.
  • SignatureFD's Entrada Therapeutics position peaked at $2.63K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.